4-Sep-2026
Health Catalyst to Participate in Upcoming Investor Conference
Globe Newswire (Mon, 31-Aug 4:05 PM ET)
PRNewswire (Thu, 6-Aug 4:03 PM ET)
Health Catalyst Reports Second Quarter 2026 Results
Globe Newswire (Thu, 6-Aug 4:03 PM ET)
Globe Newswire (Tue, 28-Jul 5:30 PM ET)
Health Catalyst’s $147 Million Vitalware Sale Sharpens AI Focus and Strengthens Balance Sheet
Market Chameleon (Thu, 4-Jun 5:52 AM ET)
Market Chameleon (Mon, 4-May 7:44 AM ET)
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Health Catalyst trades on the NASDAQ stock market under the symbol HCAT.
As of September 4, 2026, HCAT stock price declined to $1.69 with 399,206 million shares trading.
HCAT has a beta of 1.93, meaning it tends to be more sensitive to market movements. HCAT has a correlation of 0.06 to the broad based SPY ETF.
HCAT has a market cap of $127.18 million. This is considered a Micro Cap stock.
Last quarter Health Catalyst reported $70 million in Revenue and $.04 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.03.
In the last 3 years, HCAT traded as high as $11.98 and as low as $.96.
The top ETF exchange traded funds that HCAT belongs to (by Net Assets): VTI, VXF, FESM, SCHA, VHT.
HCAT has underperformed the market in the last year with a return of -48.8%, while the SPY ETF gained +19.8%. In the last 3 month period, HCAT fell short of the market, returning -12.9%, while SPY returned +2.0%. However, in the most recent 2 weeks HCAT has outperformed the stock market by returning +10.5%, while SPY returned +0.6%.
HCAT support price is $1.63 and resistance is $1.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCAT shares will trade within this expected range on the day.
